Compare Crispr Therapeutics AG (CRSP) vs Zillow Group Inc Class C (Z) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Zillow Group Inc Class C — how do they compare? Crispr Therapeutics AG trades at $53.95 (market cap $5.23B), while Zillow Group Inc Class C trades at $33.24 (market cap $7.68B). The key difference: Zillow Group Inc Class C is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Zillow Group Inc Class C nearer its low. Which is the better fit depends on your goals.
| CRSP | Z | |
|---|---|---|
Market Cap | $5.23B | $7.68B |
Sector | Health | Media |
52-Week High | $76.78 | $90.35 |
52-Week Low | $44.34 | $29.41 |
Enterprise Value | $3.65B | $7.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $54.02, up 0.95% on the day, with strong technical momentum and bullish moving average signals. The company reported a Q2 2026 loss of $0.94 per share, beating estimates, while revenue growth is driven by CASGEVY sales expansion. Analyst sentiment remains positive with a $82.67 consensus price target representing 53% upside potential.
Despite promising pipeline developments and strong analyst support, CRSP faces significant fundamental challenges including negative profit margins, substantial cash burn, and high valuation multiples. The stock's near-term performance will depend on successful clinical trial outcomes and commercial execution of its gene-editing therapies.
Zillow Group (Z) trades at $33.26, down 1.45% on the day, amid a bearish technical signal and mixed sentiment. The stock shows strong revenue growth, with Q2 2026 results beating expectations, but faces near-term pressure from a securities class action lawsuit. Valuation metrics like a P/E of 148.41 reflect high growth expectations, while profitability remains modest with a net income margin of 1.96%.
The outlook is cautious; analyst consensus targets $52.00, implying upside, but legal risks and a challenging real estate market pose headwinds. Investors should weigh the company's monetization progress against litigation overhangs and macroeconomic sensitivity for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Zillow Group Inc Class C
Zillow Group is an online real estate company that simplifies buying, selling, renting, and financing properties. It partners with agents, brokers, and landlords, combining technology with quality service. Its brands include Zillow, Trulia, StreetEasy, and Hotpads.
Read more on Z →
